Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M414569200 on April 22, 2005

J. Biol. Chem., Vol. 280, Issue 28, 26425-26434, July 15, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/28/26425    most recent
M414569200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotolo, J. A.
Right arrow Articles by Kolesnick, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotolo, J. A.
Right arrow Articles by Kolesnick, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling*

Jimmy A. Rotolo{ddagger}§, Jianjun Zhang{ddagger}, Manjula Donepudi{ddagger}, Hyunmi Lee{ddagger}, Zvi Fuks¶, and Richard Kolesnick{ddagger}||

From the {ddagger}Laboratory of Signal Transduction and Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 and the §Department of Pharmacology, Joan and Sanford I. Weill Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Received for publication, December 27, 2004 , and in revised form, April 6, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Recent evidence suggests clustering of plasma membrane rafts into ceramide-enriched platforms serves as a transmembrane signaling mechanism for a subset of cell surface receptors and environmental stresses (Grassme, H., Jekle, A., Riehle, A., Schwarz, H., Berger, J., Sandhoff, K., Kolesnick, R., and Gulbins, E. (2001) J. Biol. Chem. 276, 20589-20596; Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001) J. Biol. Chem. 276, 23954-23961). Translocation of the secretory form of acid sphingomyelinase (ASMase) into microscopic rafts generates therein the ceramide that drives raft coalescence. This process serves to feed forward Fas activation, with ~2% of full caspase 8 activation sufficient for maximal ASMase translocation, leading to death-inducing signaling complex formation within ceramide-rich platforms, and apoptosis. Here we report that treatment of Jurkat T cells with UV-C also induces ASMase translocation into rafts within 1 min, catalyzing sphingomyelin hydrolysis to ceramide and raft clustering. In contrast to Fas, UV-induced ASMase translocation and activation were caspase-independent. Nonetheless, ceramide-rich platforms promoted UV-C-induced death signaling, because ASMase inhibition or raft disruption inhibited apoptosis, improving clonogenic cell survival. These studies thus define two distinct mechanisms for biologically relevant ASMase activation within rafts; a Fas-mediated mechanism dependent upon caspase 8 and FADD, and a UV-induced mechanism independent of caspase activation. Consistent with this notion, genetic depletion or pharmacologic inhibition of caspase 8 or FADD, which render Jurkat cells incapable of sphingolipid signaling and apoptosis upon Fas ligation, did not impair these events upon UV-C stimulation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Rafts are distinct plasma membrane microdomains, comprised of cholesterol tightly packed with sphingolipids, in particular sphingomyelin, creating a liquid-ordered domain within the liquid-disordered bulk plasma membrane (1). An emerging body of evidence recognizes rafts as sites of signal transduction (1-10). One mode by which rafts transmit signals involves their coalescence into large platforms into which signaling proteins translocate, concentrate, and multimerize (11). Several groups have recently reported that ceramide, a lipid second messenger for diverse stresses, provides the driving force for coalescence of rafts into platforms (4, 6, 7, 9, 12-16). Specifically, ceramide addition to mammalian cells or model membrane bilayers is alone sufficient for platform formation (17-20). This fusagenic property of ceramide appears to derive from its unique biophysical capacity to self-associate via hydrogen bonding and van der Waal forces (12).

Ceramide may be rapidly generated by sphingomyelinase-catalyzed hydrolysis of sphingomyelin at the plasma membrane (21), or in a more prolonged fashion via de novo synthesis in the endoplasmic reticulum or mitochondria by ceramide synthases (22, 23). Acidic sphingomyelinase (ASMase),1 a sphingomyelin-specific phospholipase C (sphingomyelin phosphodiesterase) that exists in two forms, a lysosomal and secretory form, initiates a rapid stress response in many cell types (24-28). Recent data show that secretory ASMase translocates onto the outer leaflet of the plasma membrane from intracellular, presumably vesicular stores, to release ceramide within the raft-associated sphingomyelin pool, generating the ceramide therein required for raft clustering. Despite extensive studies on the downstream effects of ASMase translocation and activation (4, 7-9, 12, 25-34), little is known of the initiating events mediating its translocation onto the outer plasma membrane.

The role of ceramide-mediated raft clustering in signaling is best defined for Fas stimulation of Jurkat T cells (14, 16, 31, 36-40). In these cells, engagement of pre-trimerized Fas receptors (41) activates, within seconds, a small percentage (1-2% of maximum) of procaspase 8 and the adaptor protein FADD (15), sufficient for maximal translocation of ASMase into membrane rafts, ceramide generation, and raft coalescence into ceramide-rich platforms (14, 15). Fas oligomerizes within these ceramide-rich platforms, facilitating formation of the death-inducing signaling complex, an event essential for the other 98% of Fas-induced FADD and caspase 8 activation, and apoptosis of these cells (15). Six independent groups have published together that they all detect Fas clustering within seconds in Jurkat cells and in other cells, including SKW 6.4 and JY B cell lymphoma, H9 T cell lymphoma, Chang human conjunctiva epithelial, and mouse granulosa cells, and in primary murine spenocytes and hepatocytes (14). Consistent with this phenomenon as relevant to overall outcome, pharmacologic inhibition of raft clustering by cholesterol extraction or chelation, inhibition of ASMase activation, or sequestration of ceramide with anti-ceramide antibody renders Jurkat and some of the above-mentioned cells largely resistant to Fas-induced apoptosis (6, 16, 31, 37, 38, 42, 43).

Ceramide-mediated raft clustering also mediates stress responses for stimuli other than Fas (3, 4, 6-10). In this context, ceramide-enriched platforms transmit signals for CD40-induced interleukin-12 secretion and c-Jun kinase phosphorylation in JY B cells (4), Pseudomonas aeruginosa internalization and activation of the innate immune response in lung (7), Rituximab-induced CD20 clustering and ERK phosphorylation in Daudi and RL lymphoma cells (10), FcR{gamma}II clustering and phosphorylation in U937 human monocytic cells (3, 44), and resveratrol-, cisplatin-, and reactive oxygen species-induced apoptosis in HT29 human colon carcinoma cells and neutrophils (6, 8, 9). Hence, ceramide-mediated raft clustering into macrodomains appears to represent a generic mechanism for transmembrane signaling, rather than a specific mechanism for apoptosis induction.

The present studies address the mechanism of ASMase translocation into rafts. Jurkat cells display two distinct mechanisms, the caspase-dependent mechanism used by Fas and a previously unrecognized caspase-independent mechanism utilized by UV-C. In both instances, the outcome of translocation is ceramide generation in rafts, raft coalescence into platforms, and apoptosis. However, in the case of UV-C, although apoptosis is dependent on ceramide generation, it is independent of Fas activation or death-inducing signaling complex-mediated initiator caspase activation. These data indicate that generation of ceramide, rather than the mechanism of ASMase activation, regulates platform formation and stress-induced apoptosis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture and Stimulation—Wild-type (clone E6-1), caspase 8-/- (clone I9.2) and FADD-/- (clone I2.1) Jurkat T lymphocytes were obtained from the ATCC (Rockville, MD). Cells were grown in a 5% CO2 incubator at 37 °C in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 10 mM Hepes (pH 7.4), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 µM nonessential amino acids, 100 units/ml penicillin, and 100 µg/ml streptomycin. Prior to stimulation with UV-C or {alpha}-Fas, cells were resuspended in fresh medium and allowed to acclimate for 4 h. Cells were then treated with 50 ng/ml {alpha}-Fas CH-11 activating antibody (Upstate%20Biotechnology">Upstate Biotechnology, Lake Placid, NY) or 50 J/m2 UV-C using an FB-UVXL-1000 cross-linker (Fisher Biotech, Pittsburgh, PA), unless otherwise indicated. For platform studies, cells were incubated with CH-11 at 4 °C for 20 min to ensure uniform receptor engagement and warmed to 37 °C to initiate stimulation.

Where indicated, cells were preincubated with 10 µM z-VAD-fmk (Calbiochem, La Jolla, CA), 30 µg/ml nystatin (Sigma-Aldrich), 50 µM imipramine (Sigma-Aldrich), or 1 µg/ml mouse monoclonal {alpha}-ceramide antibody MID15B4 (Alexis Biochemicals, San Diego, CA). Nystatin, imipramine, and {alpha}-ceramide studies were performed in RPMI containing 0.5% lipid-free fetal bovine serum (HyClone, Logan UT). In each study, an aliquot of cells were stained with trypan blue to assess viability.

Apoptosis Quantitation—Apoptosis was assessed by two different techniques. Staining for terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling was performed on cells permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate at 4 °C for 5 min, according to the manufacturer's instructions (Roche Applied Science). Alternately, stimulated cells were fixed with 2% paraformaldehyde, washed with phosphate-buffered saline (PBS), and stained with 100 µl of 24 µg/ml bisbenzimide trihydrochloride solution (Hoechst #33258, Sigma-Aldrich) for 10 min. Morphologic changes of nuclear apoptosis, including chromatin condensation, segmentation, and compaction along the periphery of the nucleus or the appearance of apoptotic bodies were quantified using an Axiovert S-100 Zeiss fluorescence microscope as previously described (16). A minimum of 200 cells was examined per point.

Clonogenic Assay—Colony formation following UV-C or {alpha}-Fas CH-11 treatment was evaluated using a soft agar cloning assay as described previously (45). Briefly, cells were preincubated with nystatin and {alpha}-ceramide monoclonal antibody, or vehicle and control IgM in RPMI plus 0.5% lipid-free fetal bovine serum, and stimulated with increasing doses of UV-C or {alpha}-Fas. After 4 h, cells were suspended in RPMI medium containing 20% fetal bovine serum, 20 mM L-glutamine, and 40% methylcellulose medium, and plated in triplicate. After 14-16 days of incubation, colonies were scored and colony formation for each condition was calculated in relation to values obtained for untreated control cells. Colony survival curves were calculated by least square regression analysis, using a modification of the program FIT (46). The program fits the curves by iteratively weighted least squares to each set of dose-survival data, estimates the covariates of the survival curve parameters and the corresponding confidence regions, and plots the survival curve. It also derives curve parameters, such as the Do (the reciprocal of the slope on the exponential portion of the curve, representing the level of radiosensitivity) and the N number (measuring the size of the shoulder).

Platform Detection—Platforms were detected as previously described. Briefly, 1 x 106 Jurkat cells were stimulated with UV-C or {alpha}-Fas, fixed with 2% paraformaldehyde at the indicated times, blocked in PBS containing 1% fetal bovine serum, and then washed with PBS. Cells were stained for the raft-localized lipid GM1 with FITC-conjugated cholera toxin {beta}-subunit (2 µg/ml, Sigma-Aldrich) for 45 min at 4 °C, washed twice in PBS containing 0.1% Triton X-100, and mounted in fluorescent mounting medium (Dako, Carpenteria, CA). Fluorescence was detected using an Axiovert S-100 Zeiss fluorescence microscope equipped with a SPOT digital camera. The percentage of cells containing platforms, i.e. those in which the fluorescence condenses onto <15% of the cell surface, was determined by counting 150-250 cells per point. Alternately, platforms were identified using a mouse monoclonal {alpha}-ceramide antibody MID 15B4 IgM (1:50 dilution, Alexis Biochemicals), mouse monoclonal {alpha}-Fas CH-11 IgM (1:500 dilution, Upstate%20Biotechnology">Upstate Biotechnology) or polyclonal rabbit {alpha}-ASMase antibody 1598 (1:100 dilution) and detected using Cy3-conjugated {alpha}-mouse or {alpha}-rabbit IgM (1:500 dilution, Roche Applied Science), respectively. Rabbit polyclonal {alpha}-CD46 (1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA) was used as a negative control. In some studies, confocal images were obtained using a Leica TCS SPZ upright confocal microscope.

The rabbit polyclonal anti-ASMase antibody #1598 was generated against full-length FLAG-tagged human ASMase protein. Anti-sera was purified over a Bio-Rad T-Gel column to obtain an IgG fraction that displays specific immunoreactivity by immunoblot assay at a concentration of 100 ng/µl toward 100 ng of purified recombinant human ASMase or ASMase from 25 µg of Jurkat cell lysates. At a concentration of 200 µg/µl, #1598 quantitatively immunoprecipitates ASMase activity from 100 ng of purified ASMase and at a concentration of 200 ng/µl detects cell surface expression of ASMase by flow cytometry or confocal immunofluorescence microscopy.

Diacylglycerol Kinase Assay—Jurkat cells, stimulated with UV-C or CH-11, were incubated for the indicated times at 37 °C. Stimulation was terminated by the addition of 2 ml of chloroform:methanol:HCl (100:100:1, v/v), and ceramide was quantified by the diacyglycerol kinase assay, as described (47).

Western Blot Analysis—Jurkat cells stimulated with UV-C or CH-11 were incubated for the indicated times at 37 °C. Stimulation was terminated with ice-cold PBS, and cells were lysed in radioimmune precipitation assay buffer (25 mM HEPES (pH 7.4), 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 100 mM NaCl, 10 mM NaF, 10 mM Na2P2O7, 10 mM EDTA, and 10 µg/ml each of aprotonin and leupeptin). Samples were centrifuged at 14,000 x g, and the supernatants were added to 4x SDS-sample buffer. Lysates were separated on a 10% SDS-PAGE gel and transferred onto nitrocellulose membranes. Caspase cleavage was detected using rabbit polyclonal antibodies against caspase 3 (BD Pharmingen, San Diego, CA), caspase 8 (BD Pharmingen), or caspase 9 (Cell Signaling Technology, Beverly, MA).

FACS Analysis of ASMase Surface Expression—To detect surface ASMase by FACS, Jurkat cells were stimulated with 50 J/m2 UV-C or 50 ng/ml CH-11 at 37 °C. Stimulation was terminated after 1 min, the time of maximal ASMase translocation, by addition of ice-cold washing buffer (PBS containing 1% FCS and 0.1% NaN3), and cells were blocked on ice for 20 min using the same buffer supplemented with isotype control rabbit IgG (20 µg/ml). Cells were re-washed and incubated for 45 min with 1 µg/ml polyclonal {alpha}-ASMase 1598 antibody in PBS, followed by washing and incubation with Cy3-conjugated {alpha}-rabbit IgG. 10,000 cells were analyzed using a FACScan flow cytometer (BD Biosciences).

ASMase Activity Assay—ASMase activity was measured using a fluorescence-based, high performance liquid chromatographic assay (48). Briefly, 5 x 106 Jurkat cells were stimulated with 50 J/m2 UV-C or 50 ng/ml CH-11 at 37 °C, and at the indicated times washed with ice-cold PBS and lysed on ice in Nonidet P-40 buffer (150 mM NaCl, 25 mM Tris HCl, pH 7.5, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA, 0.1 M dithiothreitol supplemented with phenylmethylsulfonyl fluoride, leupeptin, and protease inhibitor mixture). ASMase activity was measured by incubating an equal volume of lysate in assay buffer (500 µM BODIPY-C12 sphingomyelin (Molecular Probes, Eugene OR), 0.1 mM ZnCl2, 0.1 M sodium acetate, pH 5.0, and 0.6% Triton X-100) for 60 min at 37 °C. Thereafter, the reaction was stopped by 10x dilution in ethanol, and 5 µl of the assay mixture was sampled by a WIPS 712 (Waters Corp., Milford, MA) auto-sampler equipped with a 20 x 4 mm reverse-phase Aquasil C18 column (Keystone Scientific, Bellefonte, PA). The reaction product, BODIPY-C12 ceramide, was specifically separated from substrate within 0.4-0.5 min by isocratic elution with 95% MeOH at a flow rate of 1.2 ml/min. Fluorescence was quantified using a Waters 474 (Waters Corp.) fluorescence detector set to excitation and emission wavelengths of 505 and 540 nm, respectively. The amount of product generated was calculated using a regression equation derived from a standard curve established for known amounts of BODIPY-C12 ceramide standard. Alternatively, ASMase activity was quantified by radioenzymatic assay using [N-methyl-14C]sphingomyelin (Amersham Biosciences) as substrate, as described (49). Briefly, Jurkat cells were lysed in PBS containing 0.2% Triton X-100 at the indicated times after 50 J/m2 UV-C or 50 ng/ml CH-11 stimulation. Post nuclear supernatants were assayed for activity in 250 mM sodium acetate, pH 5.0, supplemented with 0.1 mM ZnCl2, 1 mM EDTA, and 0.1% Triton X-100 in the presence of substrate. Reactions were terminated after 1 h with CHCl3:MeOH:1N HCl (100:100:1, v/v), and the product was quantified by using a scintillation counter. Because both assays yielded identical fold increases after UV-C or Fas stimulation, these data were collated. However, BODIPY-C12 sphingomyelin was less efficiently catalyzed resulting in a lower Vmax as determined by Michaelis-Menten kinetic analysis. Thus, baseline ASMase-specific activity, derived from the radioenzymatic assay, is displayed throughout this report.

Statistical Analysis—Statistical analysis was performed with Student's t test, with 95% confidence estimations.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Stress and Cytokines Generate Ceramide-rich Platforms on the Surface of Jurkat Cells—In Jurkat T lymphocytes, UV-C irradiation induces the generation of ceramide in a time- and dose-dependent manner (Fig. 1A). Total cellular ceramide levels quantified by DG kinase assay increased from 128 ± 5 to 181 ± 10 pmol/106 cells (mean ± S.E.) within 1 min of 200 J/m2 UV-C irradiation (p < 0.05 versus control), a maximally effective dose, and persisted for over 2 min before decreasing toward baseline (Fig. 1A, left panel). Ceramide generation was dose-dependent at 1 min (Fig. 1A, right panel), reaching a maximum at 50 J/m2 UV-C (p < 0.05), with an approximate ED50 of 10 J/m2.

Whereas previous studies demonstrated that Fas-induced ceramide generation occurred via translocation of ASMase from an intracellular vesicular compartment to the cell membrane (16, 31), surface expression of this enzyme was measured after UV-C. Flow cytometric analysis performed with an {alpha}-ASMase or isotype control antibody revealed that 50 J/m2 UV-C, like 50 ng/ml CH-11 {alpha}-Fas activating antibody, maximally increased ASMase expression on the outer leaflet of the plasma membrane within 1 min (Fig. 1B). To further examine the role of ASMase in UV-C-induced ceramide generation, ASMase enzyme activity was measured. ASMase specific activity rapidly increased within 1 min of 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas stimulation (Fig. 1C), from a baseline of 11.4 ± 0.7 nmol/mg/h to 18.3 ± 0.8 and 17.3 ± 0.5 nmol/mg/h, respectively (p < 0.05 each). Thus, ASMase translocation and activation correlate closely with the time course of ceramide generation, suggesting that UV-C-induced ceramide generation, like Fas (21), is ASMase-mediated.

Because ASMase surface translocation and activation in response to Fas and other stress stimuli induces ceramide generation within rafts leading to raft clustering into large platforms (2-4, 6, 8, 10, 14), UV-C-induced platform generation was determined by confocal fluorescence microscopy. In unstimulated cells, staining for ceramide or GM1, a glycosphingolipid intrinsic to rafts used as a raft marker, showed homogeneous distribution across the cell membrane, whereas surface ASMase was virtually undetectable (Fig. 1, D and E). Within seconds to minutes of exposure to 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas activating antibody, cell surface platforms enriched in ceramide and ASMase (Fig. 1D) were observed, which also contained GM1 (Fig. 1E and data not shown). Platform generation, as measured by GM1 clustering (Fig. 1F), was detected as early as 15 s post stimulation with 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas CH-11 and peaked within 30 s at 52.0 ± 4.4 and 55.6 ± 2.6% of the total population, respectively, compared with 6.4 ± 1.2% in unstimulated controls (p < 0.05 each). Platform formation was dose-dependent at 1 min (data not shown), reaching a maximum at 50 J/m2 UV-C (p < 0.05), with an ED50 identical to UV-C induced ceramide generation (Fig. 1A, right panel) of 10 J/m2. ASMase translocation into platforms was specific (Fig. 1E, upper panel), because the non-raft transmembrane glycoprotein CD46, involved in regulating the complement cascade, did not cluster in response to UV-C (Fig. 1E, lower panel) or {alpha}-Fas (data not shown).

Ceramide-rich Platforms Are Obligate for UV-C and Fas-induced Apoptosis—Because previous experiments identified ceramide as obligate for Fas-induced apoptosis in some cell types (14-16, 21, 31, 34, 37, 47, 50, 51), the requirement for UV-C-induced ceramide generation in initiating the apoptotic response was investigated. These studies used imipramine to inhibit ASMase activity, likely by increasing ASMase proteolytic degradation (21, 30). Pre-treatment of Jurkat cells with 50 µM imipramine for 30 min decreased baseline ASMase activity, abrogated UV-C and Fas-induced ASMase activation at 1 min post stimulation (Fig. 2A) and ceramide generation at 2 min (data not shown), and attenuated apoptosis at 4 h post-stimulation (Fig. 2B). These data suggest that ASMase activation is indispensable for optimal Fas- or UV-C-induced apoptosis, although they do not define the role of ceramide in this response.

To elucidate the role of ceramide-mediated raft clustering in UV-C-induced apoptotic signaling, ceramide neutralization using {alpha}-ceramide monoclonal antibody was combined with cholesterol depletion. Ceramide neutralization and cholesterol depletion have each been successfully employed in Jurkat cells to afford protection against Fas-induced platform generation and apoptosis (31), however in the present studies greater protection was achieved by using these reagents in combination rather than individually.2 Preincubation of cells with {alpha}-ceramide in combination with nystatin inhibited raft clustering 1 min post 50 J/m2 UV-C- or 50 ng/ml {alpha}-Fas stimulation (Fig. 2C), as determined by fluorescence microscopy using FITC-conjugated cholera toxin {beta}-subunit. Furthermore, inhibiting raft clustering by {alpha}-ceramide and nystatin combination treatment attenuated UV-C (5-50 J/m2)- and {alpha}-Fas (1-50 ng/ml CH-11)-induced apoptosis 4 h post stimulation (Fig. 2D) and enhanced cell viability by 2.46- and 2.42-fold, respectively, 7 days post stimulation with 50 J/m2 UV-C or 50 ng of {alpha}-Fas.3 Furthermore, {alpha}-ceramide and nystatin pretreatment yielded an approximate 1-log increase in clonogenic cell survival compared with vehicle controls after 5-50 J/m2 UV-C (Fig. 2E and not shown) or {alpha}-Fas stimulation.4 Plotting these clonogenic survival data according to the single-hit multitarget model (52) revealed that pretreatment with {alpha}-ceramide and nystatin increased the D0 of the dose-response curve from 1.6 ± 0.7 to 3.6 ± 1.1 J/m2, indicating significant (p < 0.05) protection against the reproductive mode of UV-induced cell death, with a dose-modifying value of 2.32 at the 10% survival level. Taken together, these results suggest that ceramide-mediated raft clustering at the surface of Jurkat cells is obligate for apoptotic transmembrane signal transduction induced by UV-C and that such protection is biologically relevant as evidenced by improved clonogenic survival.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 1.
UV-C- and Fas-activated ASMase mediates raft clustering into ceramide-rich platforms. A, UV-C rapidly induces ceramide generation in a time- and dose-dependent manner. Cells stimulated with 200 J/m2 for the indicated times or increasing doses of UV-C for 1 min were analyzed for ceramide content by DG kinase assay as described under "Materials and Methods." Data (mean ± S.E.) are compiled from three independent experiments performed in triplicate. B, Fas and UV-C rapidly increase surface ASMase expression. FACS analysis was performed on Jurkat cells stained with a polyclonal {alpha}-ASMase Ab 1 min post {alpha}-Fas or UV-C stimulation. Data are from one representative of three independent studies. C, Fas and UV-C elevate ASMase activity in a time-dependent manner. Cells were stimulated with 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas CH-11 antibody, and ASMase activity was determined using either BODIPY-C12 sphingomyelin or [14C]sphingomyelin as substrate and collated as under "Materials and Methods." Data (mean ± S.E.) are compiled from three independent experiments performed in triplicate. D and E, UV-C- and Fas-induced platform formation. Colocalization of ASMase with ceramide (D) or the lipid raft marker GM1 (E, upper panel) in platforms on the outer leaflet of the plasma membrane of Jurkat cells identified 1 min post {alpha}-Fas or UV-C stimulation by reconstructive confocal microscopy after staining with Cy-3-labeled {alpha}-ASMase Ab and FITC-labeled {alpha}-ceramide Ab or FITC-conjugated cholera toxin {beta}-subunit, respectively. These images are representative of over 50% of cells from three experiments in which 100 cells were analyzed. Exclusion of CD46 from platforms (E, lower panel) was identified by confocal microscopy after staining with Cy-3-labeled {alpha}-CD46 Ab and FITC-conjugated cholera toxin {beta}-subunit. F, time-dependent generation of platforms after UV-C irradiation or Fas engagement. Staining of GM1 using FITC-conjugated cholera toxin {beta}-subunit shows 50 J/m2 UV-C irradiation or 50 ng/ml Fas stimulation induce raft clustering into platforms by fluorescence microscopy. Data (mean ± S.E.) are collated from three experiments in which 200 cells were analyzed per point.

 
UV-C-induced Platform Generation Occurs Independent of Caspases—In Jurkat cells, only 2% of caspase 8 and FADD are initially recruited by ligated Fas to induce ASMase translocation into plasma membrane rafts (53, 54), generating ceramide-enriched platforms that activate the remaining 98% of caspase 8 and FADD (31, 37). To assess whether UV-C similarly activates a small percentage of caspase 8 to trigger ASMase translocation, procaspase 8 cleavage was assessed by Western blot after 200 J/m2 UV-C irradiation. Within minutes of Fas engagement, and in the same time frame as Fas-induced ASMase translocation and ceramide generation, the p43/41 and p20 active cleavage products of procaspase 8 were readily detectable by Western blot analysis (Fig. 3A). In contrast, procaspase 8 processing was not detectable for at least 30 min upon UV-C treatment (Fig. 3A), suggesting that UV-C-induced ceramide generation and platform formation occurred prior to, and thus independent of early processing of caspase 8.

To confirm that caspase 8 activation was not required for UV-C-induced raft coalescence, the effect of caspase inhibition on clustering of rafts into ceramide-rich platforms was measured. Generation of platforms by {alpha}-Fas stimulation was completely inhibited by nanomolar quantities of the pan caspase inhibitor z-VAD-fmk, whereas UV-C induced platform formation was resistant to caspase inhibition (Fig. 3B). Taken together with the Western blot analysis, these data indicate that UV-C activates platform generation by a caspase-independent mechanism, and suggest the existence of caspase-dependent and -independent mechanisms for ASMase activation.

UV-C-induced Apoptosis Occurs Independent of Caspase 8—To clarify the role of caspases in UV-C-induced cell death of Jurkat T lymphocytes, apoptosis was quantified after treatment of cells with increasing concentrations of the pan caspase inhibitor z-VAD-fmk. Although pharmacologic caspase inhibition did not impact UV-C induced formation of ceramide-rich platforms, it blocked both UV-C- and {alpha}-Fas-mediated apoptosis in a dose-dependent manner (Fig. 4A), confirming that UV-C, like {alpha}-Fas, requires cysteine-aspartate proteases for execution of apoptosis. To further examine whether caspase 8 and FADD play a role in apoptosis activated by UV-C, Jurkat T lymphocyte clones containing point mutations in the genes encoding procaspase 8 or FADD were utilized. Caspase 8-/- and FADD-/- Jurkat cells were stimulated with increasing doses of {alpha}-Fas or UV-C irradiation. At 16 h, Fas-induced apoptosis was absent in both caspase 8-/- and FADD-/- cells, even at doses that induced maximal apoptosis in wild-type cells (Fig. 4B, left panel). In contrast, UV-C-induced apoptosis was unaltered in the mutant lines compared with wild-type cells (Fig. 4B, right panel). Furthermore, equal processing of caspases 3 and 9 occurred in wild-type, caspase 8-/- and FADD-/- Jurkat cells at 4 h post UV-C irradiation, whereas processing of these caspases was absent in the mutant cell lines post Fas engagement (Fig. 4C). These data suggest that UV-C-induced apoptosis in Jurkat cells occurs independent of Fas stimulation and death-inducing signaling complex-mediated caspase 8 initiation.

UV-C-induced ASMase Surface Expression and Ceramide Generation Are Caspase-independent—To confirm the existence of both caspase-dependent and -independent ASMase activation, wild-type, caspase 8-/-, and FADD-/- Jurkat cells were stimulated with 50 ng/ml {alpha}-Fas or 50 J/m2 UV-C. Fas and UV-C each initiated rapid ASMase translocation from an intracellular pool to the cell surface of wild-type Jurkat cells, as evidenced by an increase in surface stain by FACS analysis (Fig. 1B). However, caspase 8-/- and FADD-/- Jurkat cells were unable to recruit ASMase to the membrane upon Fas engagement (Fig. 5A), whereas UV-C induced increase in {alpha}-ASMase surface stain was not impaired in these mutant cell lines (compare Figs. 1B and 5A). Consistent with these observations, caspase 8-/- and FADD-/- cells were defective in generation of ceramide (Fig. 5B) and ceramide-enriched platforms (Fig. 5C, left panel) upon Fas engagement yet retained their capacity to respond to UV-C irradiation by generating ceramide (Fig. 5B) and forming such platforms (Fig. 5C, right panel). These data indicate that UV-C-induced ASMase translocation, ceramide generation, and platform formation occur independent of caspases and that both caspase-dependent and -independent mechanisms for initiation of ASMase signaling exist. Consistent with these observations, z-VAD-fmk blocked {alpha}-Fas but not UV-C-induced ceramide generation (Fig. 5B) and platform formation (Fig. 3B).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Although numerous studies document the role of ASMase in signal transduction of apoptosis (9, 16, 31, 39, 40), senescence (55), and proliferation (56) in response to diverse stimuli, little is known of the mechanism of ASMase translocation and activation. The present study details a previously unrecognized caspase-independent pathway initiating ASMase signaling. These studies corroborate prior studies that identify caspase-independent ceramide generation in response to IgM in WEHI 231 B cells (57), hypoxia in PC12 cells (58), and dexamethasone in thymocytes (59). These prior investigations were based primarily on the use of caspase inhibitors, and the role of ASMase in these events was not investigated. The current study specifically provides information that irradiation of Jurkat cells with UV-C, an environmental stress requiring both ASMase activation (25, 26, 28, 33, 60) and ceramide generation (32, 61-63) for apoptosis induction in some cells, activates the sphingomyelin signaling pathway in the absence of functional caspase 8 or in the presence of a pan caspase inhibitor. UV-C-induced ceramide generation drives the clustering of sphingolipid rafts into platforms, an event obligate for efficient apoptosis signaling. Consistent with this paradigm, antagonism of ceramide action by sphingomyelinase inhibition, sequestration of surface ceramide with {alpha}-ceramide antibody, or cholesterol depletion inhibit UV-C-induced platform formation and apoptosis, improving cell survival as measured by the clonogenic assay.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 2.
Ceramide-rich platforms are obligate for UV-C- and Fas-induced apoptosis. A, imipramine inhibits Fas- and UV-C-induced activation of ASMase. Jurkat cells preincubated with 50 µM imipramine were left untreated or treated with 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas CH-11 antibody for 1 min. ASMase activity was analyzed as in Fig. 1C. Data (mean ± S.E.) are compiled from three experiments performed in triplicate. B, imipramine inhibits Fas- and UV-C-induced apoptosis. Apoptosis was quantified morphologically 4 h after UV-C or {alpha}-Fas CH-11 antibody stimulation by bisbenzimide staining. Data (mean ± S.E.) represent three experiments in which 200 cells were analyzed per point. C, ceramide sequestration inhibits UV-C- and Fas-induced platform formation. Staining of GM1 with FITC-conjugated cholera toxin {beta}-subunit was performed on Jurkat cells pretreated with a combination of 30 µg/ml nystatin and 1 µg/ml {alpha}-ceramide Ab followed by stimulation with 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas CH-11 antibody for 1 min. Data (mean ± S.E.) are collated from three experiments in which 200 cells were analyzed per point. D, platform formation is obligate for UV-C- and Fas-induced apoptosis and E, clonogenic cell death. Jurkat cells pretreated with a combination of 30 µg/ml nystatin and 1 µg/ml {alpha}-ceramide Ab or vehicle and irrelevant antibody control were stimulated with increasing doses of UV-C or {alpha}-Fas CH-11 antibody and apoptosis quantified after 4 h as in B. Colony formation was quantified by clonogenic assay as described under "Materials and Methods." Apoptosis data (mean ± S.E.) represent three experiments performed in triplicate in which 200 cells were analyzed per point, and clonogenic data (mean ± S.E.) were compiled from three independent experiments performed in triplicate.

 



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 3.
UV-C-induced platform generation is caspase-independent. A, Fas, but not UV-C, rapidly initiates processing of a small percentage of caspase 8. Western blot image is representative of three independent experiments. B, dose-dependent pharmacologic inhibition of Fas- but not UV-C-induced platforms by the pan caspase inhibitor z-VAD-fmk. Platforms were assessed by fluorescence microscopy of cells stained with FITC-conjugated cholera toxin {beta}-subunit 2 min post 50 J/m2 UV-C irradiation or 50 ng/ml Fas stimulation. Data (mean ± S.E.) are collated from three experiments in which 200 cells were analyzed per point.

 



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 4.
UV-C-induced apoptosis is caspase 8-independent. A, pan caspase inhibition abrogates both UV-C- and Fas-induced apoptosis. Cells were preincubated for 30 min with increasing concentrations of z-VAD-fmk, and apoptosis was quantified 16 h post UV-C or {alpha}-Fas exposure by bisbenzimide staining as in Fig. 2B. Data (mean ± S.E.) represent three experiments in which 200 cells were analyzed per point. B, genetic inhibition of caspase 8 signaling prevents Fas-, but not UV-C-induced apoptosis. Apoptosis was quantified 16 h post UV-C or {alpha}-Fas stimulation as in A. Data (mean ± S.E.) represent three experiments in which 200 cells were analyzed per point. C, Fas, but not UV-C, requires functional caspase 8 and FADD to activate initiator caspase 9 and effector caspase 3 within 2 h of stimulation. The blot is representative of three independent experiments.

 
The evidence suggests that the conversion of microscopic rafts into ceramide-rich macrodomains serves as a feed-forward mechanism for transmembrane signaling. Although ASMase is not a direct target for caspase 8, ASMase surface translocation activated by Fas, and perhaps other tumor necrosis factor superfamily receptors (64), nonetheless requires minimal caspase 8 and FADD activation. In fact <2% of maximal caspase 8 or FADD are necessary for 100% of ASMase activation, ceramide generation, platform formation, and Fas recruitment into ceramide-rich platforms in Jurkat cells. Fas oligomerizes within these platforms, activating the other 98% of caspase 8 and FADD necessary for optimal apoptosis induction. Whether Fas oligomerization is exclusively ceramide-mediated or requires concomitant reduction of sphingomyelin or cholesterol levels (65, 66) is currently unknown. As with Fas, we anticipate that UV-C similarly recruits a subset of surface proteins and downstream effector molecules into ceramide-rich platforms to transmit its signal across the plasma membrane. Whether the eventual outcome of UV-C action in Jurkat cells or other cell types requires an additional signal from damaged DNA, as suggested by the clonogenic data, is currently unknown.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 5.
UV-C activates the sphingolipid pathway independent of caspase 8 or FADD. A, genetic inhibition of caspase 8 signaling prevents Fas- but not UV-C-induced translocation of ASMase to the cell surface 1 min post stimulation. ASMase surface translocation was determined by FACS analysis using Cy-3-labeled rabbit {alpha}-ASMase Ab. Data are from one representative of three independent studies. B, pharmacologic caspase inhibition or genetic inhibition of caspase 8 signaling blocks Fas-, but not UV-C-induced ceramide generation. Jurkat cells, preincubated with caspase inhibitor or genetically lacking caspase 8 or FADD, were stimulated for 1 min with UV-C or {alpha}-Fas. Ceramide content was determined by DG kinase assay. Data (mean ± S.E.) are compiled from three independent experiments performed in triplicate. C, genetic inhibition of caspase 8 signaling prevents Fas-, but not UV-C-induced platform formation. Platform formation was quantified at the indicated times post 50 J/m2 UV-C or 50 ng/ml {alpha}-Fas stimulation by fluorescence microscopy of cells stained with FITC-conjugated cholera toxin {beta}-subunit. Data (mean ± S.E.) are collated from three experiments in which 200 cells were analyzed per point.

 
Although the exact mechanism of activation of the secretory form of ASMase is uncertain, transmission electron microscopy reveals that ASMase exists in vesicles abutting the inner plasma membrane that, upon activation, appear to fuse with the membrane and empty their content onto the extracellular surface (37). This process likely requires reorganization of microtubules and the actin cytoskeleton, as inhibition with nocodazole, a microtubule-destabilizing drug, and cytochalasin D, an actin cytoskeleton-disrupting agent abrogate ASMase translocation (15, 67). In contrast, raft disruption does not interfere with ASMase surface translocation, although it does interfere with subsequent ceramide generation, suggesting that enzymatic activity requires intact rafts for substrate recognition.5 Whether association of ASMase with rafts requires a membrane docking protein, analogous to that of the secretory phospholipases A2, which also target substrate on the exoplasmic leaflet of the plasma membrane, is currently unknown (68).

Although more than 25 reports provide genetic and pharmacologic evidence that ceramide-rich platforms are obligate for transmembrane signal transduction in response to tumor necrosis factor-superfamily (4, 8, 9, 14-16, 31, 37, 42, 69-71) and FcR{gamma}II (3) receptors, pathogens such as Pseudomonas aeroginosa and Staphylococcus aureus (7), and some chemotherapeutics, including Rituximab (10) and cisplatin (6), there is disagreement regarding their role in Fas-mediated death. Specifically, Algeciras-Schimnich et al. (72) did not detect early formation of Fas-containing platforms in SKW6.4, K50, or H9 lymphoid cell lines. Six independent groups working together were nonetheless able to detect Fas-containing platforms in Jurkat cells within the first 5 min of stimulation, and in 11 other cell lines of different origins. The inability of Algeciras-Schimnich et al. to detect platforms appears related to a staining-fixing regimen in which rapid Fas clustering was undetectable due to nonspecific antibody binding to unprotected Fc receptors (14). The results of Muppidi and co-workers (73) also differed from that of the six independent groups that published together. These investigators proposed that Fas was constitutively present in rafts in cells that undergo Type I Fas-induced death but absent from rafts in Type II cells. However, these studies examined platform formation only at 1 h, a time at which platforms generated at 1-2 min have long dissipated as the ceramide necessary for platform maintenance is metabolized rapidly (74). Furthermore, these studies used 0.5% Triton X-100 (v/v, based on the raft literature (75)) to isolate the detergent-rich membrane fraction for sucrose density resolution of raft Fas content. Although this detergent concentration is commonly used, in fact, it may be more appropriate for isolation of resident raft proteins and lipids, because proteins that traffic in and out of rafts appear less tightly associated (71, 76). We have repeated these studies in Jurkat cells and find that raft Fas must be isolated using 0.3% Triton X-100 (71), otherwise the majority of translocated Fas is extracted during raft preparation.6 We suggest that pharmacologic cholesterol depletion, confocal microscopy, and physical raft isolation using optimized detergent concentrations should be used in concert to corroborate results, rather than depending on any one of these techniques as sole evidence for platform formation or identification of raft constituents. Additionally, {alpha}-ceramide antibody and ceramide-binding protein domains hold promise as new tools to evaluate ceramide-mediated raft clustering (37).

In addition to the present studies representing the initial description of caspase-independent ASMase activation, they are also the first demonstration of environmental stress transmembrane signaling through ceramide-rich platforms. In this regard, preliminary studies show that ionizing radiation also uses ceramide-rich platforms to signal endothelial cell apoptosis,7 an event that regulates microvascular dysfunction in the gastrointestinal tract (27) and in experimental tumors in mice (29). The identification of two independent mechanisms for ASMase activation and ceramide-rich platform formation should assist in our emerging understanding of how cells respond to diverse external stresses by integrating them through ceramide-based transmembrane signaling.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants CA85704 (to R. K.) and CA52462 (to Z. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Tel.: 212-639-7558; Fax: 212-794-4342; E-mail: r-kolesnick{at}ski.mskcc.org.

1 The abbreviations used are: ASMase, acid sphingomyelinase; FADD, Fas-associated death domain; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-related kinase; FcR{gamma}II, Fc receptor {gamma}II; TUNEL, terminal dUTP nick-end labeling; FACS, fluorescence-activated cell sorting; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; z-VAD-fmk, benzyloxycarbonyl-VAD-fluoromethyl ketone; GM1, Gal{beta}1-3GalNAc{beta}1-4[sialic acid2-8]Gal{beta}1-4-Glc{beta}1-ceramide. Back

2 {alpha}-Ceramide and nystatin alone inhibited apoptosis induced by 50 ng/ml CH-11 by 28% and 23%, respectively, while co-addition resulted in 40% inhibition. Similarly, anti-ceramide and nystatin as single agents inhibited apoptosis induced by 50 J/m2 UV-C by 23% and 15%, respectively, while co-addition resulted in 47% inhibition of apoptosis. Clonogenic cell survival after 10 ng/ml CH-11 stimulation increased from 0.008 in vehicle treated to 0.20 and 0.16 in {alpha}-ceramide and nystatin alone groups, respectively, while clonogenic survival increased to 0.28 with co-addition. Back

3 J. Rotolo and R. Kolesnick, unpublished observation. Back

4 R. Kolesnick, manuscript in preparation. Back

5 A. Cremesti and R. Kolesnick, submitted for publication. Back

6 J. Rotolo and R. Kolesnick, manuscript in preparation. Back

7 B. Stancevic and R. Kolesnick, unpublished observation. Back


   ACKNOWLEDGMENTS
 
We acknowledge the contributions of Francois Paris to the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brown, D. A., and London, E. (1998) Annu. Rev. Cell Dev. Biol. 14, 111-136[CrossRef][Medline] [Order article via Infotrieve]
  2. Semac, I., Palomba, C., Kulangara, K., Klages, N., van Echten-Deckert, G., Borisch, B., and Hoessli, D. C. (2003) Cancer Res. 63, 534-540[Abstract/Free Full Text]
  3. Abdel Shakor, A. B., Kwiatkowska, K., and Sobota, A. (2004) J. Biol. Chem. 279, 36778-36787[Abstract/Free Full Text]
  4. Grassme, H., Jendrossek, V., Bock, J., Riehle, A., and Gulbins, E. (2002) J. Immunol. 168, 298-307[Abstract/Free Full Text]
  5. Cragg, M. S., Morgan, S. M., Chan, H. T., Morgan, B. P., Filatov, A. V., Johnson, P. W., French, R. R., and Glennie, M. J. (2003) Blood 101, 1045-1052[Abstract/Free Full Text]
  6. Lacour, S., Hammann, A., Grazide, S., Lagadic-Gossmann, D., Athias, A., Sergent, O., Laurent, G., Gambert, P., Solary, E., and Dimanche-Boitrel, M. T. (2004) Cancer Res. 64, 3593-3598[Abstract/Free Full Text]
  7. Grassme, H., Jendrossek, V., Riehle, A., von Kurthy, G., Berger, J., Schwarz, H., Weller, M., Kolesnick, R., and Gulbins, E. (2003) Nat. Med. 9, 322-330[CrossRef][Medline] [Order article via Infotrieve]
  8. Scheel-Toellner, D., Wang, K., Craddock, R., Webb, P. R., McGettrick, H. M., Assi, L. K., Parkes, N., Clough, L. E., Gulbins, E., Salmon, M., and Lord, J. M. (2004) Blood 104, 2557-2564[Abstract/Free Full Text]
  9. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N., and Solary, E. (2003) J. Biol. Chem. 278, 41482-41490[Abstract/Free Full Text]
  10. Bezombes, C., Grazide, S., Garret, C., Fabre, C., Quillet-Mary, A., Muller, S., Jaffrezou, J. P., and Laurent, G. (2004) Blood 104, 1166-1173[Abstract/Free Full Text]
  11. Schuck, S., and Simons, K. (2004) J. Cell Sci. 117, 5955-5964[Abstract/Free Full Text]
  12. Holopainen, J. M., Subramanian, M., and Kinnunen, P. K. (1998) Biochemistry 37, 17562-17570[CrossRef][Medline] [Order article via Infotrieve]
  13. Curtain, C. C., Looney, F. D., and Smelstorius, J. A. (1980) Biochim. Biophys. Acta 596, 43-56[Medline] [Order article via Infotrieve]
  14. Fanzo, J. C., Lynch, M. P., Phee, H., Hyer, M., Cremesti, A., Grassme, H., Norris, J. S., Coggeshall, K. M., Rueda, B. R., Pernis, A. B., Kolesnick, R., and Gulbins, E. (2003) Cancer Biol. Ther. 2, 392-395[Medline] [Order article via Infotrieve]
  15. Grassme, H., Cremesti, A., Kolesnick, R., and Gulbins, E. (2003) Oncogene 22, 5457-5470[CrossRef][Medline] [Order article via Infotrieve]
  16. Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001) J. Biol. Chem. 276, 23954-23961[Abstract/Free Full Text]
  17. Montes, L. R., Ruiz-Arguello, M. B., Goni, F. M., and Alonso, A. (2002) J. Biol. Chem. 277, 11788-11794[Abstract/Free Full Text]
  18. Veiga, M. P., Arrondo, J. L., Goni, F. M., and Alonso, A. (1999) Biophys. J. 76, 342-350[Medline] [Order article via Infotrieve]
  19. Holopainen, J. M., Lemmich, J., Richter, F., Mouritsen, O. G., Rapp, G., and Kinnunen, P. K. (2000) Biophys. J. 78, 2459-2469[Medline] [Order article via Infotrieve]
  20. Massey, J. B. (2001) Biochim. Biophys. Acta 1510, 167-184[Medline] [Order article via Infotrieve]
  21. Brenner, B., Ferlinz, K., Grassme, H., Weller, M., Koppenhoefer, U., Dichgans, J., Sandhoff, K., Lang, F., and Gulbins, E. (1998) Cell Death Differ. 5, 29-37[CrossRef][Medline] [Order article via Infotrieve]
  22. Shimeno, H., Soeda, S., Yasukouchi, M., Okamura, N., and Nagamatsu, A. (1995) Biol. Pharm. Bull. 18, 1335-1339[Medline] [Order article via Infotrieve]
  23. Bionda, C., Portoukalian, J., Schmitt, D., Rodriguez-Lafrasse, C., and Ardail, D. (2004) Biochem. J. 382, 527-533[CrossRef][Medline] [Order article via Infotrieve]
  24. Kolesnick, R. (1994) Mol. Chem. Neuropathol. 21, 287-297[Medline] [Order article via Infotrieve]
  25. Lozano, J., Menendez, S., Morales, A., Ehleiter, D., Liao, W. C., Wagman, R., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. (2001) J. Biol. Chem. 276, 442-448[Abstract/Free Full Text]
  26. Morita, Y., Perez, G. I., Paris, F., Miranda, S. R., Ehleiter, D., Haimovitz-Friedman, A., Fuks, Z., Xie, Z., Reed, J. C., Schuchman, E. H., Kolesnick, R. N., and Tilly, J. L. (2000) Nat. Med. 6, 1109-1114[CrossRef][Medline] [Order article via Infotrieve]
  27. Paris, F., Fuks, Z., Kang, A., Capodieci, P., Juan, G., Ehleiter, D., Haimovitz-Friedman, A., Cordon-Cardo, C., and Kolesnick, R. (2001) Science 293, 293-297[Abstract/Free Full Text]
  28. Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R. (1996) Cell 86, 189-199[CrossRef][Medline] [Order article via Infotrieve]
  29. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. (2003) Science 300, 1155-1159[Abstract/Free Full Text]
  30. Goggel, R., Winoto-Morbach, S., Vielhaber, G., Imai, Y., Lindner, K., Brade, L., Brade, H., Ehlers, S., Slutsky, A. S., Schutze, S., Gulbins, E., and Uhlig, S. (2004) Nat. Med. 10, 155-160[CrossRef][Medline] [Order article via Infotrieve]
  31. Grassme, H., Jekle, A., Riehle, A., Schwarz, H., Berger, J., Sandhoff, K., Kolesnick, R., and Gulbins, E. (2001) J. Biol. Chem. 276, 20589-20596[Abstract/Free Full Text]
  32. Haimovitz-Friedman, A., Kan, C. C., Ehleiter, D., Persaud, R. S., McLoughlin, M., Fuks, Z., and Kolesnick, R. N. (1994) J. Exp. Med. 180, 525-535[Abstract/Free Full Text]
  33. Huang, C., Ma, W., Ding, M., Bowden, G. T., and Dong, Z. (1997) J. Biol. Chem. 272, 27753-27757[Abstract/Free Full Text]
  34. Kirschnek, S., Paris, F., Weller, M., Grassme, H., Ferlinz, K., Riehle, A., Fuks, Z., Kolesnick, R., and Gulbins, E. (2000) J. Biol. Chem. 275, 27316-27323[Abstract/Free Full Text]
  35. Chamberlain, L. H. (2004) FEBS Lett. 559, 1-5[CrossRef][Medline] [Order article via Infotrieve]
  36. Scheel-Toellner, D., Wang, K., Singh, R., Majeed, S., Raza, K., Curnow, S. J., Salmon, M., and Lord, J. M. (2002) Biochem. Biophys. Res. Commun. 297, 876-879[CrossRef][Medline] [Order article via Infotrieve]
  37. Grassme, H., Schwarz, H., and Gulbins, E. (2001) Biochem. Biophys. Res. Commun. 284, 1016-1030[CrossRef][Medline] [Order article via Infotrieve]
  38. Garofalo, T., Misasi, R., Mattei, V., Giammarioli, A. M., Malorni, W., Pontieri, G. M., Pavan, A., and Sorice, M. (2003) J. Biol. Chem. 278, 8309-8315[Abstract/Free Full Text]
  39. Gajate, C., Del Canto-Janez, E., Acuna, A. U., Amat-Guerri, F., Geijo, E., Santos-Beneit, A. M., Veldman, R. J., and Mollinedo, F. (2004) J. Exp. Med. 200, 353-365[Abstract/Free Full Text]
  40. Eramo, A., Sargiacomo, M., Ricci-Vitiani, L., Todaro, M., Stassi, G., Messina, C. G., Parolini, I., Lotti, F., Sette, G., Peschle, C., and De Maria, R. (2004) Eur. J. Immunol. 34, 1930-1940[CrossRef][Medline] [Order article via Infotrieve]
  41. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y., and Lenardo, M. J. (2000) Science 288, 2354-2357[Abstract/Free Full Text]
  42. Gajate, C., and Mollinedo, F. (2001) Blood 98, 3860-3863[Abstract/Free Full Text]
  43. Hueber, A. O., Bernard, A. M., Herincs, Z., Couzinet, A., and He, H. T. (2002) EMBO Rep. 3, 190-196[CrossRef][Medline] [Order article via Infotrieve]
  44. Hillyard, D. Z., Jardine, A. G., McDonald, K. J., and Cameron, A. J. (2004) Atherosclerosis 172, 219-228[CrossRef][Medline] [Order article via Infotrieve]
  45. Dai, Y. C., Lu, X. Q., and Fang, Z. (1992) In Vitro Cell Dev. Biol. 28A, 685-686[Medline] [Order article via Infotrieve]
  46. Albright, N. (1987) Radiat. Res. 112, 331-340[Medline] [Order article via Infotrieve]
  47. Gulbins, E., Bissonnette, R., Mahboubi, A., Martin, S., Nishioka, W., Brunner, T., Baier, G., Baier-Bitterlich, G., Byrd, C., and Lang, F. (1995) Immunity 2, 341-351[CrossRef][Medline] [Order article via Infotrieve]
  48. He, X., Chen, F., Dagan, A., Gatt, S., and Schuchman, E. H. (2003) Anal. Biochem. 314, 116-120[CrossRef][Medline] [Order article via Infotrieve]
  49. Wiegmann, K., Schutze, S., Machleidt, T., Witte, D., and Kronke, M. (1994) Cell 78, 1005-1015[CrossRef][Medline] [Order article via Infotrieve]
  50. Paris, F., Grassme, H., Cremesti, A., Zager, J., Fong, Y., Haimovitz-Friedman, A., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001) J. Biol. Chem. 276, 8297-8305[Abstract/Free Full Text]
  51. Grullich, C., Sullards, M. C., Fuks, Z., Merrill, A. H., Jr., and Kolesnick, R. (2000) J. Biol. Chem. 275, 8650-8656[Abstract/Free Full Text]
  52. Elkind, M. M., and Sutton, H. (1960) Radiat. Res. 13, 556-593[Medline] [Order article via Infotrieve]
  53. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) EMBO J. 14, 5579-5588[Medline] [Order article via Infotrieve]
  54. Scaffidi, C., Kischkel, F. C., Krammer, P. H., and Peter, M. E. (2000) Methods Enzymol. 322, 363-373[Medline] [Order article via Infotrieve]
  55. Armour, C. A., Eliopoulos, A. G., Dawson, C. W., Young, L. S., and Wakelam, M. J. (1997) Biochem. Soc. Trans. 25, S588[Medline] [Order article via Infotrieve]
  56. Fang, W., Nath, K. A., Mackey, M. F., Noelle, R. J., Mueller, D. L., and Behrens, T. W. (1997) Am. J. Physiol. 272, C950-C956[Medline] [Order article via Infotrieve]
  57. Chen, L., Kim, T. J., and Pillai, S. (1998) Mol. Immunol. 35, 195-205[CrossRef][Medline] [Order article via Infotrieve]
  58. Yoshimura, S., Banno, Y., Nakashima, S., Takenaka, K., Sakai, H., Nishimura, Y., Sakai, N., Shimizu, S., Eguchi, Y., Tsujimoto, Y., and Nozawa, Y. (1998) J. Biol. Chem. 273, 6921-6927[Abstract/Free Full Text]
  59. Cifone, M. G., Migliorati, G., Parroni, R., Marchetti, C., Millimaggi, D., Santoni, A., and Riccardi, C. (1999) Blood 93, 2282-2296[Abstract/Free Full Text]
  60. Komatsu, M., Takahashi, T., Abe, T., Takahashi, I., Ida, H., and Takada, G. (2001) Biochim. Biophys. Acta 1533, 47-54[Medline] [Order article via Infotrieve]
  61. Chung, H. S., Park, S. R., Choi, E. K., Park, H. J., Griffin, R. J., Song, C. W., and Park, H. (2003) Exp. Mol. Med. 35, 181-188[Medline] [Order article via Infotrieve]
  62. Jenkins, G. M., Richards, A., Wahl, T., Mao, C., Obeid, L., and Hannun, Y. (1997) J. Biol. Chem. 272, 32566-32572[Abstract/Free Full Text]
  63. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. (1996) Nature 380, 75-79[CrossRef][Medline] [Order article via Infotrieve]
  64. Wiegmann, K., Schwandner, R., Krut, O., Yeh, W. C., Mak, T. W., and Kronke, M. (1999) J. Biol. Chem. 274, 5267-5270[Abstract/Free Full Text]
  65. Delmas, D., Rebe, C., Micheau, O., Athias, A., Gambert, P., Grazide, S., Laurent, G., Latruffe, N., and Solary, E. (2004) Oncogene 23, 8979-8986[CrossRef][Medline] [Order article via Infotrieve]
  66. London, M., and London, E. (2004) J. Biol. Chem. 279, 9997-10004[Abstract/Free Full Text]
  67. Grassme, H., Bock, J., Kun, J., and Gulbins, E. (2002) J. Biol. Chem. 277, 30289-30299[Abstract/Free Full Text]
  68. Lambeau, G., Ancian, P., Nicolas, J. P., Beiboer, S. H., Moinier, D., Verheij, H., and Lazdunski, M. (1995) J. Biol. Chem. 270, 5534-5540[Abstract/Free Full Text]
  69. Ha, H., Kwak, H. B., Le, S. W., Kim, H. H., and Lee, Z. H. (2003) Exp. Mol. Med. 35, 279-284[Medline] [Order article via Infotrieve]
  70. Cottin, V., Doan, J. E., and Riches, D. W. (2002) J. Immunol. 168, 4095-4102[Abstract/Free Full Text]
  71. Bock, J., Szabo, I., Gamper, N., Adams, C., and Gulbins, E. (2003) Biochem. Biophys. Res. Commun. 305, 890-897[CrossRef][Medline] [Order article via Infotrieve]
  72. Algeciras-Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., and Peter, M. E. (2002) Mol. Cell. Biol. 22, 207-220[Abstract/Free Full Text]
  73. Muppidi, J. R., and Siegel, R. M. (2004) Nat. Immunol. 5, 182-189[CrossRef][Medline] [Order article via Infotrieve]
  74. Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994) J. Exp. Med. 180, 1547-1552[Abstract/Free Full Text]
  75. Sproul, T. W., Malapati, S., Kim, J., and Pierce, S. K. (2000) J. Immunol. 165, 6020-6023[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Uhlig and E. Gulbins
Sphingolipids in the Lungs
Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1100 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Patschan, J. Chen, A. Polotskaia, N. Mendelev, J. Cheng, D. Patschan, and M. S. Goligorsky
Lipid mediators of autophagy in stress-induced premature senescence of endothelial cells
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1119 - H1129.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. Wrasidlo, A. Mielgo, V. A. Torres, S. Barbero, K. Stoletov, T. L. Suyama, R. L. Klemke, W. H. Gerwick, D. A. Carson, and D. G. Stupack
The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8
PNAS, February 19, 2008; 105(7): 2313 - 2318.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Reinehr, A. Sommerfeld, V. Keitel, S. Grether-Beck, and D. Haussinger
Amplification of CD95 Activation by Caspase 8-induced Endosomal Acidification in Rat Hepatocytes
J. Biol. Chem., January 25, 2008; 283(4): 2211 - 2222.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Y. H. Zeidan, B. X. Wu, R. W. Jenkins, L. M. Obeid, and Y. A. Hannun
A novel role for protein kinase C{delta}-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury
FASEB J, January 1, 2008; 22(1): 183 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. H. Zeidan and Y. A. Hannun
Activation of Acid Sphingomyelinase by Protein Kinase C{delta}-mediated Phosphorylation
J. Biol. Chem., April 13, 2007; 282(15): 11549 - 11561.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. Xu, J. Jin, W. Hu, W. Sun, J. Bielawski, Z. Szulc, T. Taha, L. M. Obeid, and C. Mao
Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P
FASEB J, September 1, 2006; 20(11): 1813 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Megha, O. Bakht, and E. London
Cholesterol Precursors Stabilize Ordinary and Ceramide-rich Ordered Lipid Domains (Lipid Rafts) to Different Degrees: IMPLICATIONS FOR THE BLOCH HYPOTHESIS AND STEROL BIOSYNTHESIS DISORDERS
J. Biol. Chem., August 4, 2006; 281(31): 21903 - 21913.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/28/26425    most recent
M414569200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotolo, J. A.
Right arrow Articles by Kolesnick, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotolo, J. A.
Right arrow Articles by Kolesnick, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement